Telaprevir for Patients with Previously Treated Hepatitis C Virus Infection

Patients who received telaprevir-based regimens achieved higher rates of sustained virologic response than patients who received standard care.

Recent phase II trial results have shown that treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection achieved higher sustained virologic response (SVR) rates with regimens that combined peginterferon alfa-2a (PEG), ribavirin, and telaprevir than with the standard PEG and ribavirin regimen (JW Gastroenterol Apr 29 2009).

To determine the efficacy of telaprevir-based regimens in treatment-experienced HCV genotype 1 patients, investigators conducted an industry-sponsored, randomized, phase II study that evaluated SVR rates in patients who received one of four treatment regimens:

The T24PR48 group (113 patients) received telaprevir (1125-mg loading dose and then 750 mg every 8 hours) for 24 weeks and PEG (180 µg weekly) and ri…

Reviewing Author

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Atif Zaman, MD, MPH

Disclosures

Nothing to disclose

Telaprevir for Patients with Previously Treated Hepatitis C Virus Infection

Topics

Reviewing Author